147 related articles for article (PubMed ID: 33371687)
21. Investigating the Impact of OGT Inhibition on Doxorubicin- and Docetaxel-Induced Cytotoxicity in PC-3 and WPMY-1 Cells.
Makwana V; Dukie AS; Rudrawar S
Int J Toxicol; 2020; 39(6):586-593. PubMed ID: 32851890
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
23. Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
Newell M; Goruk S; Mazurak V; Postovit L; Field CJ
Breast Cancer Res Treat; 2019 Sep; 177(2):357-367. PubMed ID: 31236812
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Cε.
Aziz MH; Shen H; Maki CG
J Biol Chem; 2012 Aug; 287(35):29825-36. PubMed ID: 22773829
[TBL] [Abstract][Full Text] [Related]
25. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
26. Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro.
Vancsik T; Forika G; Balogh A; Kiss E; Krenacs T
Cancer Med; 2019 Aug; 8(9):4292-4303. PubMed ID: 31183995
[TBL] [Abstract][Full Text] [Related]
27. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect.
Pore SK; Choudhary A; Rathore B; Ganguly A; Sujitha P; Kumar CG; Agawane SB; Kumar JM; Scaria V; Pillai B; Banerjee R
Biomaterials; 2013 Sep; 34(28):6804-17. PubMed ID: 23773821
[TBL] [Abstract][Full Text] [Related]
28. RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.
Guo J; Yang Y; Yang Y; Linghu E; Zhan Q; Brock MV; Herman JG; Zhang B; Guo M
Oncotarget; 2015 Feb; 6(6):4202-13. PubMed ID: 25638156
[TBL] [Abstract][Full Text] [Related]
29. Effect of apoptosis and response of extracellular matrix proteins after chemotherapy application on human breast cancer cell spheroids.
Oktem G; Vatansever S; Ayla S; Uysal A; Aktas S; Karabulut B; Bilir A
Oncol Rep; 2006 Feb; 15(2):335-40. PubMed ID: 16391851
[TBL] [Abstract][Full Text] [Related]
30. Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.
Patel K; Doddapaneni R; Sekar V; Chowdhury N; Singh M
Mol Pharm; 2016 Jun; 13(6):2049-58. PubMed ID: 27070720
[TBL] [Abstract][Full Text] [Related]
31. Self-Assembled Supramolecular Nanoparticles for Targeted Delivery and Combination Chemotherapy.
Li B; Feng Z; He L; Li W; Wang Q; Liu J; Huang J; Zheng Y; Ma Y; Yang X; Wang K
ChemMedChem; 2018 Oct; 13(19):2037-2044. PubMed ID: 30024095
[TBL] [Abstract][Full Text] [Related]
32. Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.
Neitzel C; Seiwert N; Göder A; Diehl E; Weber C; Nagel G; Stroh S; Rasenberger B; Christmann M; Fahrer J
Cells; 2019 Jul; 8(8):. PubMed ID: 31366086
[TBL] [Abstract][Full Text] [Related]
33. Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Wu T; Chen W; Zhong Y; Hou X; Fang S; Liu CY; Wang G; Yu T; Huang YY; Ouyang X; Li HQ; Cui L; Yang Y
Mol Cancer Ther; 2017 Apr; 16(4):717-728. PubMed ID: 27903750
[TBL] [Abstract][Full Text] [Related]
34. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
[TBL] [Abstract][Full Text] [Related]
35.
Kazemi M; Emami J; Hasanzadeh F; Minaiyan M; Mirian M; Lavasanifar A; Mokhtari M
Recent Pat Anticancer Drug Discov; 2020; 15(4):341-359. PubMed ID: 33023456
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells.
da Rocha MCO; da Silva PB; Radicchi MA; Andrade BYG; de Oliveira JV; Venus T; Merker C; Estrela-Lopis I; Longo JPF; Báo SN
J Nanobiotechnology; 2020 Mar; 18(1):43. PubMed ID: 32164731
[TBL] [Abstract][Full Text] [Related]
37. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
38. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
39. Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer.
Kocdor H; Ates H; Aydin S; Cehreli R; Soyarat F; Kemanli P; Harmanci D; Cengiz H; Kocdor MA
Drug Des Devel Ther; 2015; 9():3899-909. PubMed ID: 26251569
[TBL] [Abstract][Full Text] [Related]
40. Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim.
Park HK; Lee JE; Lim J; Jo DE; Park SA; Suh PG; Kang BH
BMC Cancer; 2014 Jun; 14():431. PubMed ID: 24927938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
